Secondary malignant neoplasm of female breast HER2/Neu Positive
Item
histologically or cytologically confirmed metastatic breast carcinoma that is her2 positive
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
Measurable Disease
Item
measurable disease as defined by the recist criteria
boolean
C1513041 (UMLS CUI [1])
Life Expectancy
Item
life expectancy greater than or equal to 6 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Antineoplastic Agents
Item
received any anticancer medications in the 28 days prior to enrollment into this study
boolean
C0003392 (UMLS CUI [1])
Antineoplastic Agents | Breast Carcinoma Excluded
Item
received any anticancer medications for cancers other than breast cancer within 6 months prior to enrollment in this study.
boolean
C0003392 (UMLS CUI [1])
C0678222 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
Deep Vein Thrombosis
Item
history of deep venous thrombosis within the last year
boolean
C0149871 (UMLS CUI [1])
Medical contraindication Warfarin Low dose
Item
contraindication to low dose warfarin therapy
boolean
C1301624 (UMLS CUI [1,1])
C0043031 (UMLS CUI [1,2])
C0445550 (UMLS CUI [1,3])
Cardiomyopathy
Item
clinically significant cardiomyopathy
boolean
C0878544 (UMLS CUI [1])
INCB007839 | trastuzumab | lapatinib
Item
prior treatment with incb007839 or trastuzumab or lapatinib
boolean
C4305800 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])